Could more chemo stop sarcoma spread? new trial aims to find out
NCT ID NCT03805022
First seen Oct 31, 2025 · Last updated Jun 20, 2026 · Updated 29 times
Summary
This Phase 3 trial is testing whether adding three extra cycles of chemotherapy before surgery can help prevent cancer spread in people with high-risk soft-tissue sarcoma. About 351 participants will be randomly assigned to standard treatment or standard treatment plus extra chemo. The main goal is to see if the extra chemo improves how long people live without the cancer spreading.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for NON-METASTATIC SOFT-TISSUE SARCOMA are added.
Genom att skicka in godkänner du våra Användarvillkor
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
Genom att skicka in godkänner du våra Användarvillkor
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
-
Contact
Email: •••••@•••••
Locations
-
CHRU Strasbourg
RECRUITINGStrasbourg, 67200, France
Contact Email: •••••@•••••
-
CHU Dupuytren
RECRUITINGLimoges, 87042, France
Contact
Contact
-
Centre Georges François Leclerc
RECRUITINGDijon, 21079, France
Contact
Contact
-
Centre Léon Bérard
RECRUITINGLyon, 69373, France
Contact
Contact
-
Insitut du Cancer
RECRUITINGMontpellier, 34298, France
Contact Email: •••••@•••••
Contact
-
Institut Bergonie
RECRUITINGBordeaux, 33076, France
Contact
Contact Email: •••••@•••••
-
Institut Claudius Regaud
RECRUITINGToulouse, 31052, France
Contact Email: •••••@•••••
Contact
-
Institut Gustave Roussy
NOT_YET_RECRUITINGVillejuif, 94800, France
Contact
Contact
-
Institut Paoli Calmettes
RECRUITINGMarseille, 13273, France
Contact
Contact
-
Institut de Cancérologie de l'Ouest - Site René Gauducheau
RECRUITINGSaint-Herblain, 44805, France
Contact
Contact
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Doxorubicin, ifosfamide, or dacarbazine (chemotherapy drugs)
What this could lead to
If successful, this could lead to a more effective chemotherapy regimen that delays or prevents cancer spread in high-risk soft-tissue sarcoma patients.
What could go wrong
This is an early Phase 3 trial, so results are not yet proven. Chemotherapy has significant side effects, and the extra cycles may not improve outcomes or could cause more harm.
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.